Core Viewpoint - The company, Jindawei (002626.SZ), announced that its subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., has received a veterinary drug approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the product Pyrantel, with the approval number 102091173 [1] Group 1 - The approval signifies a regulatory milestone for the company in the veterinary pharmaceutical sector [1] - The product Pyrantel is expected to enhance the company's product portfolio and market presence in the veterinary medicine industry [1]

Core Viewpoint - The company Jindawei (002626) announced that its subsidiary Jiangsu Chengxin Pharmaceutical Co., Ltd. has received the veterinary drug approval number from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the product with the generic name Praziquantel [1] Company Summary - Jindawei's subsidiary Jiangsu Chengxin Pharmaceutical has obtained a significant regulatory approval, which may enhance its product portfolio and market presence in the veterinary drug sector [1]

Group 1: Company Overview - The company primarily engages in the research, production, and sales of nutritional health foods (including raw materials and finished products) and feed additives [2][3] - The production of health food raw materials and feed additives mainly occurs domestically, with a high export ratio; finished health food products are primarily produced and sold overseas, showing significant growth through cross-border e-commerce [3] Group 2: Product Development and Market Position - The company utilizes synthetic biology as a foundational technology for large-scale production of various raw materials, including Coenzyme Q10, NMN, NADH, Vitamin K2, and others [3] - Coenzyme Q10 holds the largest global market share, demonstrating notable cost and scale advantages [3] - The company aims to reduce production costs for products like astaxanthin, DHA, and EPA to enhance market competitiveness [3] Group 3: Brand and Sales Strategy - The company owns two major health food brands, Doctor's Best and Zipfizz, with production capabilities for capsules, tablets, and powders [3][4] - Doctor's Best is a well-known health brand in North America, showing steady growth, while Zipfizz maintains stable performance with new products developed for the U.S. market [4] - The marketing strategy for domestic health food business focuses on market insights, product strategy, resource integration, and data-driven upgrades to create market-leading products [4] Group 4: Financial Performance - The company's performance growth in the first half of 2025 is primarily attributed to increased sales of Coenzyme Q10, vitamins, and domestic health products [3]